ECCO 2020 - Optimisation of the treat-to-target approach looks to be a promising step towards improving quality of life and disease outcomes in patients with ulcerative colitis (UC) and Crohn’s disease (CD), and as such, many experts are pushing for the introduction of more stringent treatment targets. Watch expert faculty provide valuable insight on key issues.
In both ulcerative colitis and Crohn’s disease, the invasion of the intestinal mucosa by leukocytes is now an important clinical focus (Park & Jeen, 2018). Anti-integrin therapies which block the action of integrins and endothelial cell adhesion molecules include natalizumab and also vedolizumab which targets trafficking of leukocytes. Find out more about their mechanisms of action, explore the relevant study data and review recent data shared at Congresses.